KYMERA THERAPEUTICS INC (KYMR)
Health Care · biotechnology · NASDAQ
Kymera Therapeutics is pioneering oral, targeted protein degradation medicines designed to deliver biologic-like efficacy for underserved patients in immunology and beyond.
What KYMERA THERAPEUTICS INC does
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, targeted protein degradation (TPD) medicines. The company aims to address complex disease-causing proteins that have been previously considered undruggable, with a primary focus on immunology and the goal of providing biologic-like efficacy through convenient, daily oral pills.
Themes: targeted protein degradation, immunology, oral small molecule therapeutics, atopic dermatitis therapy, asthma treatment
Fundamentals
- Price$113.46 as of 2026-10-20 close
- Market cap$9.4B as of 2026-07-31 (share count; price 2026-10-20)
- 1-year return+87.5% 2025-10-20 close $60.50 → 2026-10-20 close $113.46
- P/En/a negative earnings
- Net margin-794.0% FY2025, SEC XBRL
- ROE-19.7% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)-16.7% FY2025, SEC XBRL
- Revenue CAGR (3y)-5.7% SEC XBRL
- Beta1.45 as of 2026-09-02
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How KYMR compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
KYMR is not currently in any published Top 10 list. Its scores are below.
Top 10 score
22.8 #1256 of 1,265 scored · #144 of 146 in Health Care
Trend 77th (over the past 12 months this stock beat the market by 73.0 percentage points) and valuation 29th (price to book 6.3); weakest is financial health (1st, free cash flow margin -597.6%).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $65M | -$76M | -$61M | -$0.62 | -$54M† | $473000† |
| Q1 FY2026 2026-03-31 | $34M | -$84M | -$69M | -$0.71 | -$89M | $434000 |
| Q4 FY2025 2025-12-31 | $3M† | -$98M† | -$87M† | -$0.98† | -$67M† | $106000† |
| Q3 FY2025 2025-09-30 | $3M | -$93M | -$82M | -$0.94 | -$27M† | $181000† |
| Q2 FY2025 2025-06-30 | $11M | -$85M | -$77M | -$0.95 | -$60M† | $695000† |
| Q1 FY2025 2025-03-31 | $22M | -$74M | -$66M | -$0.82 | -$79M | $467000 |
| Q4 FY2024 2024-12-31 | $7M† | -$81M† | -$71M† | -$0.89† | -$62M† | $936000† |
| Q3 FY2024 2024-09-30 | $4M | -$72M | -$62M | -$0.82 | -$50M† | -$189000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$124M
- Short-term investments$567M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How KYMERA THERAPEUTICS INC looks technically
KYMERA THERAPEUTICS INC (KYMR) is trading 19.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 316 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 3 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 10% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 19.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $115.09 | $115.09 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $94.64 | $94.64 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 115.815. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 316 trading days ago — a "golden cross", a bullish long-term signal | 316 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 11, below the 25 that marks a real trend) | 10.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($101.75 to $116.20) — its "stochastic" reading is 81 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 81.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $130.05 | $130.05 |
|---|---|---|
| From the 52-week high | it is 12.8% below its 52-week high (its highest price of the past year) | -12.8% |
| Above the 52-week low | it is 105.3% above its 52-week low (its lowest price of the past year) | +105.3% |
| Below the 52-week high | it is 12.8% below its highest point of the past year | 12.8% |
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 44 trading days ago | 44 sessions |
| All-time high | its highest closing price on record is $130.05 (set on 2026-06-25) | $130.05 |
| Given back of the 52-week move | over the past year its closes ranged ($55.80 to $127.31), and it has given back roughly a quarter of its rise from last year’s low — 19% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $80.83 to $83.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.4% |
| From the all-time high | it is 12.8% below its all-time high | -12.8% |
| Nearest price level | it is trading 3.4% above a support level at $109.58 — a price it turned at twice since 2026-07-13, most recently on 2026-09-15. Since 2024-10-21 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.4% |
| All-time low | its lowest closing price on record is $9.60 (set on 2023-11-02) | $9.60 |
| Above the all-time low | it is 1081.9% above its all-time low | +1,082% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 10% of the past ~6 months), which often precedes a bigger move | 10th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.35 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.35 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $104.07 and $116.03 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $104.07 – $110.05 – $116.03 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 3.5 daily ranges above its 200-day average price (19.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.83× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.0% since the prior reading | +0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.6% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-09-17 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 19 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +8.28% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 4.6 percentage points (the stock lost 3.6% while the market gained 1.0%) | -4.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.5 percentage points (the stock gained 2.2% while the market gained 3.6%) | -1.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 22.0 percentage points (the stock gained 30.5% while the market gained 8.5%) | +22.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 73.0 percentage points (the stock gained 87.5% while the market gained 14.6%) | +73.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 3.1% of the share price. | -0.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 18% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $96.46 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | +17.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $114.13 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -0.6% |
Head and shoulders, bearish — broke down · entry $116.57 · 71 sessions in
Price levels it has turned at before
KYMR last closed at $113.46 on 2026-10-20. Since 2024-10-21 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $109.58 | Support | 3.4% below the last close | turned there twice · 2026-07-13 to 2026-09-15 |
| $120.36 | Resistance | 6.1% above the last close | turned there twice · 2026-07-07 to 2026-07-20 |
| $102.37 | Support | 9.8% below the last close | turned there twice · 2025-12-08 to 2026-10-06 |
| $89.80 | Support | 20.9% below the last close | turned there twice · 2026-04-15 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $115.81.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $81.42 and $94.56 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $115.81.
This reading has stood for 3 trading days, since 2026-10-16.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Broke down to a new 20-day low · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · bollinger bands
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 23 analysts
- Mean price target$139.35 range $111.00 – $180.00; median $139.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KYMR
- Consensus EPS estimate-$1.27 next reporting period, as of 2026-10-17
- Estimate change, 30 days-$0.01609 from -$1.25, on 2026-09-12, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Uncertainty and significant costs associated with clinical development of novel therapeutic modalities.","Dependence on strategic collaborations and licensing partners for clinical progression and funding.","History of net losses and the requirement for substantial additional capital to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of KYMR's 10-Q filed 2026-08-05 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05): states KT-485/SAR447971 'is being evaluated in a Phase 1 clinical trial' rather than the prior description.
- Newer filing (2026-08-05): states 'We are also collaborating with Gilead Sciences, Inc. ("Gilead") on the development of our oral CDK2 molecular glue degrader, KT-200, which is currently in IND-enabling studies.'
- Newer filing (2026-08-05): includes net losses of $61.2 million and $130.4 million for the three and six months ended June 30, 2026, respectively, and $76.6 million and $142.2 million for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05): states as of June 30, 2026 accumulated deficit of $1,196 million.
- Newer filing (2026-08-05): replaces 'To date' with 'Through June 30, 2026' in the gross proceeds sentence.
- Removed:
- Older filing (2026-04-30): included the sentence 'which Sanofi plans to advance into clinical testing in 2026'.
- Older filing (2026-04-30): included the sentence 'In June 2025, we announced a strategic collaboration with Gilead Sciences, Inc. ("Gilead") to develop novel oral molecular glue degraders for CDK2. In April 2026, Gilead exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader. Gilead is expected to progress the program into IND-enabling studies to support an IND filing in 2027.'
- Older filing (2026-04-30): included net losses of $69.2 million and $65.6 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-04-30): stated as of March 31, 2026 accumulated deficit of $1,135 million.
- Older filing (2026-04-30): used 'To date' in the gross proceeds sentence.
- Reworded:
- KT-485/SAR447971 program description changed from 'which Sanofi plans to advance into clinical testing in 2026' (older) to 'which is being evaluated in a Phase 1 clinical trial' (newer).
- CDK2/Gilead collaboration description changed from a sequence of announcement, option exercise, and expected IND-enabling studies timing in 2027 (older) to 'KT-200, which is currently in IND-enabling studies' (newer).
- Gross proceeds sentence changed from 'To date' (older) to 'Through June 30, 2026' (newer).
- Net loss reporting changed from quarterly figures for Q1 2026 and Q1 2025 (older) to quarterly and six-month figures for Q2 2026, H1 2026, Q2 2025, and H1 2025 (newer).
- Accumulated deficit as-of date and amount changed from March 31, 2026 ($1,135 million) and December 31, 2025 ($1,066.0 million) (older) to June 30, 2026 ($1,196 million) and December 31, 2025 ($1,066 million) (newer).
- Notes:
- The newer filing text appears truncated mid-sentence at 'expand and improve the capabilities of our drug discovery platfo' and the older filing text appears truncated mid-sentence at 'advance research and development related activities to ex', limiting full comparison of subsequent bullet points and any changes after that point.
Risk Factors
- Added:
- Newer filing (2026-08-05) includes introductory text stating: 'Our business involves a high degree of risk. You should carefully consider the material and other risks and uncertainties described and summarized below...' which is not present in the older filing.
- Newer filing (2026-08-05) states: 'As of June 30, 2026, our cash and cash equivalents and marketable securities were $1,505 million.'
- Newer filing (2026-08-05) states accumulated deficit of $1,196.4 million as of June 30, 2026.
- Newer filing (2026-08-05) reports net losses of $61.2 million and $130.4 million for the three and six months ended June 30, 2026, respectively.
- Newer filing (2026-08-05) reports net losses of $76.6 million and $142.2 million for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05) states 'As of June 30, 2026 we had approximately $1,505 million of cash and cash equivalents and marketable securities' in the funding risk factor (text appears truncated).
- Removed:
- Older filing (2026-04-30) includes introductory text stating: 'The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements...' which is not present in the newer filing.
- Older filing (2026-04-30) states: 'As of March 31, 2026, our cash and cash equivalents and marketable securities were $1,546 million.'
- Older filing (2026-04-30) states accumulated deficit of $1,135 million as of March 31, 2026.
- Older filing (2026-04-30) reports net losses of $69.2 million and $65.6 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-04-30) states 'As of March 31, 2026 we had approximately $1,546 million of cash and cash equivalents and marketable securities, which we expect will be sufficient to fund our operations into 2029...' in the funding risk factor.
- Reworded:
- The introductory paragraph of the Risk Factors section was substantially revised between the older filing (2026-04-30) and the newer filing (2026-08-05), changing from guidance on reading the Quarterly Report to a focus on investment risk considerations.
- The page number at the bottom of the first page of risk factors changed from 34 (older filing, 2026-04-30) to 37 (newer filing, 2026-08-05).
- Notes:
- The newer filing text appears truncated at the end ('which we expect will b'), so changes after that point in the newer document cannot be assessed.
- The comparison is limited to the provided excerpts; the older filing excerpt also appears to continue beyond the provided text.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 9 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 30 days · read to 2026-10-160 buys · 6 sells ($3M) — 1 selling insider
- Last 90 days · read to 2026-10-160 buys · 9 sells ($4M) — 2 selling insiders
- Last 180 days · read to 2026-10-160 buys · 179 sells ($403M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-01. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KYMR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding KYMR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 20,974,602
- Reported value $2,405,157,633
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about KYMR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
KYMR had 9,910,014 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
KYMR had 11.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.97 days to cover at the same settlement.
- Reported short interest (shares) 9,910,014
- Short interest (% of shares outstanding) 11.9%
- Prior settlement (shares) 10,530,809
- Reported change -5.9%
- Days to cover (reported) 11.97
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KYMR vs…
KYMERA THERAPEUTICS INC is found in…
Frequently asked questions
What does KYMERA THERAPEUTICS INC (KYMR) do?
Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, targeted protein degradation (TPD) medicines. The company aims to address complex disease-causing proteins that have been previously considered undruggable, with a primary focus on immunology and the goal of providing biologic-like efficacy through convenient, daily oral pills.
What sector is KYMERA THERAPEUTICS INC (KYMR) in?
KYMERA THERAPEUTICS INC (KYMR) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are KYMERA THERAPEUTICS INC's (KYMR) competitors?
Notable peers of KYMERA THERAPEUTICS INC (KYMR) include Arvinas, C4 Therapeutics, Nurix Therapeutics and Monte Rosa Therapeutics. This peer set is informational only — not financial advice.
Is KYMERA THERAPEUTICS INC (KYMR) overbought or oversold right now?
KYMERA THERAPEUTICS INC (KYMR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KYMR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.